Angiotech Pharmaceuticals, Inc.
Vancouver V6A1B6 CAN
Share:
Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction
CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStem-® in the treatment of acute myocardial infarction (AMI). The companies believe that...
Read More »Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction
CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStemÃ-® in the treatment of acute myocardial infarction (AMI). The companies believe that...
Read More »Absorbable Sutures eliminate use of knots.
Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...
Read More »Absorbable Sutures eliminate use of knots.
Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...
Read More »Angiotech Receives European Approval for Quill® SRS Wound Closure Product
New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its Quill-® Self-Retaining System (SRS). Launched early in the year in the United States, Quill®...
Read More »Angiotech Receives European Approval for Quill-® SRS Wound Closure Product
New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its QuillÃ-® Self-Retaining System (SRS). Launched early in the year in the United States,...
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS® Express2(TM) Coronary Stent System
Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS-® Express2(TM) Coronary Stent System
Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Approval for the TAXUS® Express2(TM) Stent System
VANCOUVER, April 3 - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner, Boston Scientific Corporation (NYSE:BSX), announced today that Boston Scientific has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to market its TAXUS-® Express2(TM)...
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Approval for the TAXUS-® Express2(TM) Stent System
VANCOUVER, April 3 - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner, Boston Scientific Corporation (NYSE:BSX), announced today that Boston Scientific has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to market its TAXUSÃ-® Express2(TM)...
Read More »Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction
CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStem-® in the treatment of acute myocardial infarction (AMI). The companies believe that...
Read More »Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction
CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStemÃ-® in the treatment of acute myocardial infarction (AMI). The companies believe that...
Read More »Absorbable Sutures eliminate use of knots.
Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...
Read More »Absorbable Sutures eliminate use of knots.
Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...
Read More »Angiotech Receives European Approval for Quill® SRS Wound Closure Product
New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its Quill-® Self-Retaining System (SRS). Launched early in the year in the United States, Quill®...
Read More »Angiotech Receives European Approval for Quill-® SRS Wound Closure Product
New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its QuillÃ-® Self-Retaining System (SRS). Launched early in the year in the United States,...
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS® Express2(TM) Coronary Stent System
Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....
Read More »Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS-® Express2(TM) Coronary Stent System
Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....
Read More »Angiotech to Market Vascular Wrap(TM)/e0PTFE Graft Combination Product through its Own European Sales and Distribution Networks
VANCOUVER, May 10 / -- Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, today announced that it has amended its agreement with Edwards Lifesciences Corporation ( Edwards"), regarding the distribution of Angiotech's Vascular Wrap(TM) paclitaxel-eluting mesh/ePTFE graft combination product. Angiotech now has the exclusive rights to distribute the...
Read More »Angiotech to Market Vascular Wrap(TM)/e0PTFE Graft Combination Product through its Own European Sales and Distribution Networks
VANCOUVER, May 10 / -- Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, today announced that it has amended its agreement with Edwards Lifesciences Corporation ( Edwards"), regarding the distribution of Angiotech's Vascular Wrap(TM) paclitaxel-eluting mesh/ePTFE graft combination product. Angiotech now has the exclusive rights to distribute the...
Read More »